Quick Answer
ARS Pharmaceuticals, Inc. reported Total Assets of $327.65 million for fiscal year 2025.
ARS Pharmaceuticals, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $327.65M | -6.7% |
| 2024 | $351.15M | +50.6% |
| 2023 | $233.19M | -17.1% |
| 2022 | $281.44M | +358.0% |
| 2021 | $61.45M | -84.4% |
| 2020 | $394.80M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $372.80M | +71.3% | +18.9% |
| June 30, 2025 | $313.47M | +41.2% | -4.2% |
| March 31, 2025 | $327.32M | +43.8% | -6.8% |
| December 31, 2024 | $351.15M | +50.6% | +61.4% |
| September 30, 2024 | $217.60M | -12.5% | -2.0% |
| June 30, 2024 | $221.97M | -14.2% | -2.5% |
| March 31, 2024 | $227.58M | -16.1% | -2.4% |
| December 31, 2023 | $233.19M | -17.1% | -6.2% |
- ARS Pharmaceuticals, Inc. showed a decrease of -6.7% in Total Assets compared to the prior fiscal year.
- Over the 2020–2025 period, ARS Pharmaceuticals, Inc.’s total assets has declined by 17.0% (from $394.80 million to $327.65 million).
- The most recent figure is from ARS Pharmaceuticals, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 9, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: